Background HER2 is one of the most extensively studied oncogenes in solid tumors.
However, the association between tumor microenvironment (TME) and HER2 mutation …

The ErbB/HER family of receptor tyrosine kinases consists of four cell surface glycoproteins:
epidermal growth factor 1 (EGFR or ErbB1), ErbB2 (c-Neu or human EGF receptor 2 …

Options for the treatment of squamous cell lung carcinoma expanded in recent years with
the introduction of the immune checkpoint inhibitors into routine clinical practice in both the …

肿瘤分子靶向治疗是指以肿瘤发生发展相关的关键分子作为靶点, 利用抑制剂, 阻断剂,
抗体等药物进行抗肿瘤治疗的手段. 分子靶向治疗具有特异性强, 副作用小等特点 …

Background An accurate and comprehensive assessment of harms is a fundamental part of
an accurate weighing of benefits and harms of an intervention when making treatment …

We aimed to explore the treatment efficacy of first-generation epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) for lung squamous cell carcinoma (SCC) …

Simple Summary Although the LUX-Lung 8 trial has demonstrated the clinical benefit of
afatinib as a second-line treatment for squamous cell carcinoma of the lung (LSCC), data on …

Background Liver metastasis is the major challenge in the treatment for malignant tumors.
Genomic profiling is increasingly used in the diagnosis, treatment and prediction of …

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the
first-line treatment for EGFR-mutant non-small cell lung cancer. Toxicities related to EGFR …

Background: The aim of this study is to report tumoral genetic mutations observed at high
sequencing depth in a lung squamous cell carcinoma (SqCC) sample. We describe the …